Oncology

Minimize toxicity, Maximize efficacy

ACK-122/BCC-903

Drug delivery technology to address Actinic Keratosis (AK) and Basal Cell Carcinoma (BCC) skin cancer. Aquavit has established ongoing relationships with several University Medical Centers and is testing to deliver high dosage of efficacious compounds directly into the skin with minimal adverse reactions. The unmet needs here are mostly the issue of tolerability, patient compliance and persistency. Our new development will directly address and solve the core issue by minimizing systemic toxicity while delivering potent therapeutic agents directly onto the affected site.